PTC Therapeutics, Inc. (PTCT) — Analysis Summary
PTC Therapeutics, Inc. (PTCT) has a market cap of $5.25B with year-over-year revenue growth of +114.5%. Net margin stands at 39.4%. The stock trades at a P/E ratio of -136.8.
Key Takeaways
- Revenue changed +114.5% year-over-year
- Net margin of 39.4%
- P/E ratio of -136.8
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, PTCT posted revenue growth of +114.5% and trades at a P/E of -136.8.
PTC Therapeutics, Inc. (PTCT)
PREVIOUS CLOSE 2026-10-12 · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Revenue fell 41.7% vs the prior period.
Net income turned negative after a profitable prior period.
Shareholder equity is negative, which can signal balance-sheet stress.
Operating margin (12.5%) exceeds gross margin (0.0%) — check for other operating income or data classification issues
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.
Sector
PHARMACEUTICAL PREPARATIONS
Employees
991
Headquarters
WARREN, NJ
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.